ArticleGels (Basel, Switzerland)2026
Design and Biological Evaluation of a Gelatin/Recombinant Type III Collagen/CMC Composite Hydrogel for Wound Healing.
Article in Gels (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Effective chronic skin wound healing remains challenging due to excessive inflammation, insufficient vascular support, and impaired extracellular matrix remodeling. By rationally designing and integrating complementary biomaterials, it is possible to synergistically tailor physicochemical properties and biological performance for tissue repair and regeneration. In this study, a gelatin-based composite hydrogel incorporating recombinant type III collagen (rColIII) and carboxymethyl cellulose (CMC) was developed via EDC/NHS-mediated crosslinking and evaluated for wound repair. By tuning the rColIII/CMC ratio, the hydrogel mechanical modulus (G') increased from ~1.2 kPa to ~2.6 kPa, and enzymatic degradation could be modulated, as reflected by changes in the remaining material mass. The optimized Gel/rCol/CMC-1 formulation supported 3T3 cell migration (1.8-fold increase at 24 h) and promoted a pro-regenerative (M2-like) macrophage phenotype in vitro. In a full-thickness diabetic wound model, Gel/rCol/CMC-1 accelerated wound closure (82.3 ± 4.7% vs. 56.9 ± 5.1% at day 14) and enhanced tissue quality, evidenced by more organized collagen deposition and increased CD31
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.